TP53 and hematopoietic and lymphoid cell neoplasm: Interestingly, 5q deletion is also the most frequent arm-level CNA in TP53-mutated tumors with myelodysplastic syndrome (MDS; refs. 50, 51), suggesting 5q is a common target of deletion in TP53-mutated solid and hematologic cancers.